New Phase 3 Study Findings Show IMBRUVICA ® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Pharmaceuticals | Rituxan | Study